Statistics for Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial
Total visits
| views | |
|---|---|
| Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial | 81 |
Total visits per month
| views | |
|---|---|
| July 2024 | 0 |
| August 2024 | 0 |
| September 2024 | 0 |
| October 2024 | 0 |
| November 2024 | 0 |
| December 2024 | 0 |
| January 2025 | 0 |
File Visits
| views | |
|---|---|
| Pembrolizumab versus docetaxel for previously treated.pdf | 25 |
Top country views
| views | |
|---|---|
| United States | 43 |
| Chile | 15 |
| United Kingdom | 1 |
| Israel | 1 |
| Mexico | 1 |
Top city views
| views | |
|---|---|
| Miami | 36 |
| Santiago | 11 |
| Alameda | 5 |
| Campbell | 1 |
| Colina | 1 |
| London | 1 |
| Sacramento | 1 |
| Tel Aviv | 1 |
| Zapopan | 1 |